Comprehensive analysis reveals PLK3 as a promising immune target and prognostic indicator in glioma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Polo-like kinase 3 (PLK3) promotes glioma progression and immune suppression. High PLK3 expression correlates with malignancy and poor prognosis, suggesting PLK3 as a potential therapeutic target for glioma.
Area Of Science
- Oncology
- Molecular Biology
- Immunology
Background
- Polo-like kinase 3 (PLK3) is implicated in cell cycle and stress response, with elevated expression in carcinomas.
- The role and prognostic significance of PLK3 in glioma remain largely uncharacterized.
Purpose Of The Study
- To investigate the expression, function, and prognostic value of PLK3 in glioma.
- To explore the impact of PLK3 on glioma progression and the tumor immune microenvironment.
Main Methods
- PLK3 expression analysis in glioma datasets.
- In vitro and in vivo studies using PLK3 overexpression and knockdown models.
- Immunohistochemistry for PLK3 and immune cell infiltration.
- Correlation analysis with immune checkpoints like PD-1/PD-L1.
Main Results
- Increased PLK3 expression is linked to higher glioma malignancy and poorer patient prognosis.
- PLK3 promotes glioma progression and suppresses T-cell infiltration (CD8+ and CD4+).
- PLK3 shows synergistic interactions with other immune checkpoint molecules.
Conclusions
- PLK3 overexpression drives glioma progression and immune suppression.
- PLK3 is a potential prognostic biomarker and therapeutic target for glioma.
- PLK3 influences T-cell and neutrophil responses in the glioma microenvironment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
